Pulse Medical Completes Series C Financing to Build a High-End Structural Heart Disease Medical Device Innovation Platform

VCBeat learned at the first time,Guangdong Pulse Medical Technology Co., Ltd.(AbbreviationPulse Medical) CompletedCWheelFinancing, this round of financing was led byFor Future CapitalAndYuecai Bio-Pharmaceutical FundJoint Investment,Going Far and Achieving TogetherAct as the exclusive financial advisor.

Pulse Medical was founded in Zhuhai in 2014, focusing onCardiovascular Medical Device R&D and ProductionThe company adopts a deep "medical-engineering integration" R&D model, fully leveraging the unique role of senior experts on the clinical front line who have an in-depth understanding of patient needs. This is conducive to overcoming the shortcomings of existing products, absorbing the advantages of existing products, significantly reducing trial-and-error costs and time, and creatively designing new products with globally leading standards.

The company has developedSeries of Products for Structural Heart Disease Interventional Devices, and has created several firsts in China: the world's only dual-body plug-type left atrial appendage occluder is about to be commercially available; the world’s first single-rivet double-disc structure patent foramen ovale (PFO) occluder that can cross the septum is about to enter clinical trials. At the same time, the company is actively developing a variety of innovative cardiovascular medical devices, committed to building a leading high-end medical device innovation platform for structural heart disease in China.

Pulse Medical's Leftear Left Atrial Appendage Occluder was recommended as one of the "Six Outstanding Chinese Original Research" cardiovascular medical devices at the 2020 China Interventional Therapeutics Conference (CIT-2020) to participate in the 2020 European Association of Percutaneous Cardiovascular Interventions (EuroPCR-2020). The product development team delivered a special report at EuroPCR-2020, unveiling the latest clinical research data on the Leftear Left Atrial Appendage Occluder to a global audience and receiving high acclaim from experts worldwide. On June 30, 2020, the "Learning Power" platform of the Publicity Department of the Central Committee of the Communist Party of China reported on the progress and safe, effective clinical trial data of Pulse Medical's Leftear Left Atrial Appendage Occluder, as presented by the research team during their special report at EuroPCR-2020.

Since its establishment, the company has been closely collaborating with senior experts in the cardiovascular field from multiple top-tier tertiary hospitals, practicing an in-depth "medical-engineering integration" R&D model. An in-depth analysis of the actual effects of similar products from Europe and America in clinical trials and clinical use within East Asia serves as a crucial source of information and data for the development of high-end cardiovascular medical devices produced in China. Innovating by standing on the shoulders of giants is one of the shortcuts to surpassing them.

The in-depth collaboration between the engineering technology experts in Pulse Medical's R&D department and senior experts from clinical frontlines can significantly shorten the trial-and-error process, reduce R&D costs, accelerate development speed, and ultimately lead to the creation of world-class high-end medical devices. There are differences between the physiological structures of East Asians and those of Europeans and Americans, with some aspects showing significant distinctions. Physical structure is a crucial factor in the functioning of medical devices; therefore, the development of medical devices for East Asians must be based on the physiological characteristics of East Asians!

Atrial fibrillation (AF) is the most common type of arrhythmia. In China, there are over 13 million AF patients (approximately 65% of whom have non-valvular atrial fibrillation), and this number increases annually with the aging population. Thrombosis caused by AF often leads to severe consequences, with the risk of ischemic stroke in AF patients being more than five times higher than in healthy individuals. Over 95% of thrombi in non-valvular AF patients originate from the left atrial appendage (LAA). Traditional anticoagulant drug treatments have significant side effects on the human body. Left atrial appendage closure (LAAC) is a modern alternative for preventing thrombosis in patients with non-valvular atrial fibrillation, replacing traditional anticoagulant therapies.

Patent Foramen Ovale (PFO) is a type of structural heart disease that cannot be detected during the perinatal examination stage in pregnant women. The foramen ovale generally closes within the first year after an infant's birth, and if it remains unclosed beyond the age of 3, it becomes "Patent Foramen Ovale (PFO)." Clinical symptoms of PFO include dizziness, headache, syncope, cerebral ischemia (TIA), and cerebral infarction. Anatomical statistics indicate that the incidence rate of Patent Foramen Ovale (PFO) is 30% between ages 1 to 29, 25% between ages 30 to 79, and 20.2% in those over 80 years old. With advancements in PFO closure surgery and increased awareness among patients about the risks associated with PFO, demand has been growing.

Pulse Medical has established a self-owned R&D and production base in Zhuhai High-tech Industrial Development Zone, which is equipped with an annual...30,000 setsLeft Atrial Appendage Occluder Production Line &30,000 setsPFO Occluder Production Line, Capable of Supporting the Company's Annual Net Profit Scale inRMB 4.50 billionThe above.

Pulse Medical R&D and Production Base

Since its establishment, Pulse Medical has successively obtainedChen De Capital, Mountain Blue Capital, Future Capital, Merchants Zhizhuanwith the strong support of renowned medical funds, and also receivedZhuhai Local Venture Capital FundWith the support, it has now grown into a high-end medical device R&D platform for structural heart disease with influence in the Greater Bay Area. With the backing of Future Capital and Zhongyin Yuecai, Pulse Medical will reach a higher new level at a faster speed!

Chairman Ruan Chengmin, Founder of Pulse MedicalExpressed: "We are very grateful for the support from new and old shareholders such as Future Capital and Zhongyin Yuecai, and also thank Xingyuan Zhihe for their professional services. Since starting the business, we have faced many difficulties, but with the help of institutional investors, Pulse Medical has grown steadily, one step at a time each year. We will continue to deepen the integration of 'medical and engineering.'’R&D Model: Develop high-end products with significant clinical demand potential to provide better quality, advanced cardiovascular medical device products for East Asians, including those in China.

Zhao Yang, Managing Partner of Weilai Capital"It said: 'The combination of medical and engineering R&D model of Pulse Medical has a continuous competitive advantage. VCBeat is optimistic about the platform-based R&D capabilities of Pulse Medical and will continue to provide support in terms of funding, R&D, and channels in the future.'"

Meng Shengrong, Investment Director of BOC YucaiPulse Medical has developed multiple innovative products for structural heart disease using a research and development model that combines medical and engineering expertise. We are optimistic about the field of structural heart disease and recognize Pulse Medical's product development capabilities. The Yuecai Biomedical Fund hopes to work with the company to provide patients with more high-end cardiovascular device products. We will continue to focus on outstanding innovation and entrepreneurship teams in the broader health sector, promoting the successful industrialization of innovative products in the biopharmaceutical and healthcare industry.

Weilai Capital was founded in March 2018. It is a leading comprehensive industrial investment fund in China, with investment areas covering healthcare and technology. The fund manages 1.5 billion yuan in capital and nearly 8 billion yuan in assets. In the medical field, Weilai Capital has successively invested in pharmaceutical new retail, assisted reproduction, cardiac intervention, early cancer screening, artificial pancreas, and other sectors.

BOC Yuet Finance Equity Investment Fund Management (Guangdong) Co., Ltd. was jointly established by Guangdong Yuet Finance Investment Holding Co., Ltd. and BOC Group Investment Co., Ltd. It mainly focuses on five major investment areas: healthcare, new energy, advanced manufacturing, consumer goods, and infrastructure. The cumulative scale of funds managed exceeds 40 billion yuan.

StartPointAdvisors is a financial advisory firm specializing in the healthcare industry. Established in 2020, the company’s team consists of professionals from well-known institutions in the industry, bringing extensive practical experience. The company currently has offices in Beijing, Suzhou, and Guangzhou. Since its inception, StartPointAdvisors has achieved full coverage of the healthcare sector, earning a strong reputation and positive recognition within the industry. It is now considered one of the most representative emerging investment banks in China’s healthcare field.